Want to see APYX full AI Analyst Report?
EarningsQ2 2026 Earnings Report
APYX Q2 2026 EPS Results
Actual EPS-$0.07
Consensus EPS-$0.08
Beat/MissBeat by +$0.01
One Year Ago EPS-$0.09
APYX Q2 2026 Revenue Results
Actual Revenue$13.88M
Expected Revenue$13.18M
Beat/MissBeat by +$709.00K
YoY Revenue Growth+22.08%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
APYX Upcoming Earnings
Apyx Medical's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
APYX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented solid commercial and clinical momentum: double-digit top-line growth (22% total, 28% surgical aesthetics), improved gross profit/margin and narrower operating and adjusted EBITDA losses, supported by FDA clearance for power liposuction and favorable clinical data. Offsetting risks include continued OEM decline, increased operating cash use and near-term manufacturing/cost pressures for new Power Lipo units, plus tariff-related cost uncertainty. On balance, the positive revenue and margin trends, clinical validation, product approvals and reaffirmed guidance outweigh the challenges.Company Guidance
Quarterly Revenue Growth
Total revenue of $13.9M in Q2 2026, up 22% year-over-year from $11.4M, driven primarily by Surgical Aesthetics growth.
Surgical Aesthetics Momentum
Surgical Aesthetics revenue increased 28% to $12.4M (from $9.7M), driven by AYON Body Contouring System sales, increased international Renuvion generator sales and higher domestic single-use handpiece volume.
Improved Profitability Metrics
Gross profit rose 25% to $8.9M and gross margin improved to 63.9% (from 62.3% a year ago). Loss from operations improved to $1.8M (vs $2.6M prior-year) and adjusted EBITDA loss narrowed to $0.7M (from $2.0M).
Regulatory and Product Milestones (Power Lipo & AYON)
Received expanded FDA 510(k) clearance to add power liposuction to AYON, conducted a limited commercial launch and began initial commercial shipments in June 2026; management expects >95% of new AYON purchasers to include Power Lipo.
Clinical Evidence Strengthening the Platform
Retrospective study (113 patients) showed Renuvion + liposuction delivered higher patient satisfaction, fewer abdominoplasties and revisions with comparable complication rates; prospective Avéli + Renuvion data showed measurable improvement in cellulite/skin laxity and histological collagen/elastin increases through 180 days.
Geographic Revenue Expansion and Guidance Reaffirmation
Domestic revenue rose 21% to $9.4M and international revenue rose 24% to $4.5M. Reaffirmed 2026 revenue guidance of $59.0M–$60.0M (vs $52.8M in 2025) and surgical aesthetics guidance of $54.0M–$55.0M (vs $45.3M in 2025).
Liquidity Position and Multi-Year Runway
Cash and cash equivalents of $27.6M at June 30, 2026, with management stating expected sufficient liquidity into 2028 based on current projections and cost controls.
Commercial Awareness and Marketing Momentum
Broader market awareness initiatives (e.g., Miami Swim Week Body by Apex showcase) and growing surgeon engagement following AYON's commercial launch, reinforcing adoption trends.
APYX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed